Codiak BioSciences, Inc. reports results for the quarter ended in September - Earnings Summary

Codiak BioSciences,.

03/11/2022 20:50

* Codiak BioSciences, Inc.  CDAK.OQ  reported a quarterly
adjusted
loss of 59 cents​​ per share for the quarter ended in September.
The mean expectation of three analysts for the quarter was for a
loss of 82 cents per share.
    * Revenue fell 54.9% to $522.00 thousand from a year ago;
analysts
expected $587.67 thousand. 
    * Codiak BioSciences, Inc.'s reported EPS for the quarter
was a
loss of 77 cents​.
    * The mean earnings estimate of analysts had fallen by
about 32.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Codiak BioSciences, Inc. shares had risen by 16.1% this
quarter and lost 91.8% so far this year.
    * The company reported a quarterly loss of $19.28 million.
    * Wall Street's median 12-month price target for Codiak
BioSciences, Inc. is $7.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
3 at 08:50 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.82          -0.59          Beat
 Jun. 30 2022      -0.84          -0.30          Beat
 Mar. 31 2022      -0.89          -0.36          Beat
 Dec. 31 2021      -0.94          -0.74          Beat